HHS Panel on Antiretroviral Guidelines for Adults and Adolescents Accepting Nominations for New Members
The Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents (or the Panel) is accepting nominations for a new community member and additional scientific/clinical members.
Panel members critically evaluate the latest HIV treatment-related information and prepare guidelines revisions. The Panel is seeking new members available to serve a 4-year term beginning March 2013, with potential for reappointment for an additional term.
Nominations must be received by October 15, 2012.
Complete details on new member qualifications and instructions regarding nominations are available:
Study Evaluates Risk Factors for Chronic Kidney Disease in HIV-Infected Individuals Initiating Antiretroviral Therapy
“To examine long-term effects of antiretroviral therapy (ART) on kidney function, we evaluated the incidence and risk factors for chronic kidney disease (CKD) among ART-naive, HIV-infected adults and compared changes in estimated glomerular filtration rates (eGFR) before and after starting ART. …
“Three thousand, three hundred and twenty-nine patients met entry criteria, contributing 10099 person-years of observation on ART. ART was associated with a significantly slower rate of eGFR decline (from -2.18 to -1.37ml/min per 1.73m per year; P=0.02). The incidence of CKD defined by eGFR thresholds of 60, 45 and 30ml/min per 1.73m was 10.5, 3.4 and 1.6 per 1000 person-years, respectively. In adjusted analyses black race, hepatitis C coinfection, lower time-varying CD4 cell count and higher time-varying viral load on ART were associated with higher CKD risk, and the magnitude of these risks increased with more severe CKD. Tenofovir and a ritonavir-boosted protease inhibitor (rPI) was also associated with higher CKD risk … , which developed in 5.7% of patients after 4 years of exposure to this regimen-type. …
“ART was associated with reduced CKD risk in association with CD4 cell restoration and plasma viral load suppression, despite an increased CKD risk that was associated with initial regimens that included tenofovir and rPI.”
More information is available:
